Protalix BioTherapeutics Stock
Protalix BioTherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dror Bashan
- Employees
- 226
- Market cap
- $211 M
- IPO
- 15/05/1998
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the…
Protalix BioTherapeutics stock: price history
1D
-3.0%
1W
-5.8%
1M
-2.2%
6M
+12.9%
YTD
+45.6%
1Y
+9.2%
2Y
+140.4%
5Y
+113.0%
10Y
-46.0%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~37% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Protalix BioTherapeutics
Analyst assessment of Protalix BioTherapeutics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
5
BUY
2
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 09/09/2026
Protalix BioTherapeutics stock metrics
P/E
10.87
P/B
2.93
EV/EBITDA
7.34
RETURN ON EQUITY
5.3%
NET MARGIN
19.0%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.1%
FLOAT SHARES
77,446,550
AVG. DAILY VOLUME (30D)
876,972
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Protalix BioTherapeutics stock
What does Protalix BioTherapeutics do?
Protalix BioTherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dror Bashan, the company employs around 226 people.
The IPO was on 15/05/1998; the stock trades on AMEX under the ticker PLX.
What do analysts say about Protalix BioTherapeutics stock?
7 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Protalix BioTherapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 37% stronger than usual.
Does Protalix BioTherapeutics pay a dividend?
No, Protalix BioTherapeutics currently does not pay a dividend.
Which stocks are comparable to Protalix BioTherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Protalix BioTherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Protalix BioTherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.